Have a personal or library account? Click to login
Hepatic Steatosis in Patients with Chronic Viral Hepatitis C Treated with Direct Acting Antivirals Cover

Hepatic Steatosis in Patients with Chronic Viral Hepatitis C Treated with Direct Acting Antivirals

Open Access
|Aug 2023

Abstract

Hepatic steatosis is a frequent pathological finding in patients with chronic viral C infection (HCV) and can be independently associated with increased alcohol consumption, type 2 diabetes, obesity and hyperlipidemia. All these factors can lead to the development of hepatic steatosis in patients with HCV. There are several noninvasive techniques and scores used for diagnosing and quantifying liver steatosis. Successful eradication of HCV with interferon-free treatment regimens has been suggested to improve the level of hepatic steatosis. The precise mechanisms responsible for these beneficial effects are currently under investigation, but it is thought that the decrease in hepatic inflammation and viral replication contribute to the resolution of hepatic steatosis. Moreover, the overall enhancement in liver health and metabolic factors may also have a significant impact.

DOI: https://doi.org/10.2478/inmed-2023-0247 | Journal eISSN: 1220-5818 | Journal ISSN: 1220-5818
Language: English
Page range: 55 - 60
Published on: Aug 8, 2023
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2023 Oana Irina Gavril, Irina Mihaela Esanu, Ioana Madalina Zota, Iolanda Valentina Popa, Lidia Iuliana Arhire, Diana Tatarciuc, Alexandra Mastaleru, Andrei Drugescu, Radu Sebastian Gavril, Mariana Graur, Florin Mitu, published by Romanian Society of Internal Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.